For example, prescriptions of the ALK inhibitor ceritinib for the treatment of ALK-positive, advanced NSCLC decreased, but the ALK inhibitors lorlatinib and brigatinib, which were approved in 2019, and the ALK inhibitor alectinib, which was approved in 2017, are additional drugs for the treatment of NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.